“A company that constantly
challenges
for a prosperous and
healthy life for mankind”
Renhaim Inc. is a dynamically evolving biotechnology company committed to
enhancing the promotion of robust and thriving human life through advancements
in genomic technology, particularly the mRNA platform.
Our company thrives on a youthful and vibrant business culture,
effectively implementing developmental initiatives grounded in open communication,
freedom, and equality.
With unwavering dedication, we are determined to realize our vision of becoming a global leader
in healthcare, harnessing unique technologies and strategic developmental approaches.
Kang, Taejin CEO of
Renhain Inc.
Scientific Advisory Board
Kim, Hang-rae
- Technical Advisor of Renhaim Inc.
- Professor, Department of Medicine,
Seoul National University School of Medicine
- a visiting professor at Yale University School of Medicine
- Yale University School of Medicine, Post-Doc
- Bionia, Senior Researcher
- Doctor of Microbiology and Immunology,
Seoul National University School of Medicine
Larry Kwak
- Technical Advisor of Renhaim Inc.
- Vice President and Deputy Director, City of Hope
- Winner of Ho-Am Prize in Medicine in 2016
- Time’s list of most influential 100 people in 2010
- Master of Cancer Vaccine
Shin, Hyun-moo
- Associate Professor, Department of Medicine,
Seoul National University College of Medicine
- Univ. of Massachusetts medical School, Post-Doc
- Univ. of Massachusetts, Amherst, doctor of science
Lee, Chang-han
- Assistant Professor, Department of Medicine,
Seoul National University College of Medicine
- Univ. of Texas at Austin, Research associate
- Univ. of Texas at Austin, Post-Doc research fellow
- Doctor of Molecular Science and Engineering, Ajou University